This article is the second part of a two-part series on the history of clinical research regulation in India. Part One examined the foundational period from the colonial era through the emergence of structured clinical trial governance, including the Drugs and Cosmetics Act 1940, the formation of CDSCO, the Indian GCP Guidelines of 2001, and the Revised Schedule Y of 2005. This article picks up at the point where rapid growth in global trial activity began exposing the limits of that foundational framework.
Introduction
By the mid-2000s, India had positioned itself as one of the world's most attractive destinations for international clinical research. The revised Schedule Y (2005) had aligned India's clinical trial requirements more closely with international standards. The TRIPS-compliant product patent regime (2005) had demonstrated India's commitment to intellectual property frameworks that pharmaceutical companies required. A large, treatment-naive, genetically diverse patient population and a growing base of GCP-trained investigators made the scientific case for India compelling.
What followed was a period of rapid growth — and then a crisis that nearly dismantled the industry entirely.
The period from 2008 to 2019 is the most consequential decade in the history of Indian clinical research regulation. It encompasses a collapse in public and judicial confidence, a period of severe regulatory restriction that drove sponsors away from India, and ultimately a comprehensive legislative overhaul that produced the most sophisticated clinical trial regulatory framework India has ever had. Understanding this arc — what went wrong, why, and how the system responded — is essential context for anyone operating in India's clinical research environment today.
Rapid Growth and the Emergence of Systemic Concerns (2008–2011)
The volume of clinical trials conducted in India grew dramatically in the years following Schedule Y's revision. Between 2005 and 2011, the number of new clinical trial applications to CDSCO increased several-fold. Global pharmaceutical companies, attracted by the scientific, logistical, and cost advantages that India offered, increasingly included Indian sites in multinational trial programs.
This growth exposed structural vulnerabilities in India's regulatory and ethical oversight infrastructure that had not been apparent at lower trial volumes:
Informed Consent Failures
Multiple investigations — by parliamentary committees, journalists, and civil society organizations — documented serious deficiencies in informed consent processes across clinical trial sites. Participants, often from economically vulnerable populations with limited health literacy, were found to have signed consent forms without adequate understanding of the nature of their participation, the experimental status of the treatment, or the risks involved. In some documented cases, consent had been obtained in languages participants did not speak, or by individuals without appropriate authority or training.
The informed consent failures were not isolated incidents — they reflected a systemic absence of the patient education, language-appropriate materials, and independent oversight that genuine informed consent requires.
The Compensation Crisis
The question of compensation for trial-related injury became the most politically visible regulatory issue of this period. India had no clearly defined legal framework specifying when compensation was owed to trial participants, how injury relatedness was to be determined, or what quantum of compensation was appropriate. Reports of participant deaths and serious injuries — some in trials that had been improperly designed or monitored — with little or no compensation provided to affected families generated intense public and media attention.
A parliamentary standing committee investigation of trial-related deaths between 2005 and 2012 documented hundreds of deaths in clinical trials, though the causal relationship between trial participation and death was contested in many cases. The absence of a transparent, standardized determination process — and the perception that sponsors and investigators faced no meaningful accountability — fundamentally undermined public trust.
Oversight Gaps at the Investigator and Site Level
The rapid expansion of India's trial portfolio had outpaced the capacity of CDSCO and Ethics Committees to provide adequate oversight. Key structural gaps included:
Investigator overload: Some principal investigators were simultaneously listed on 10, 20, or more active clinical trials — a volume incompatible with the active scientific and safety oversight that GCP requires of principal investigators. Regulatory systems had no mechanism to detect or limit this concentration.
Ethics Committee quality variation: Hundreds of institutional Ethics Committees operated across India with no registration requirement, no minimum composition standards, and no external accountability. The quality of ethical review varied enormously — from genuinely rigorous independent review to perfunctory approval processes that provided no meaningful participant protection.
Monitoring deficits: CDSCO's capacity for clinical trial site inspections was limited relative to the volume of active trials. The combination of an under-resourced regulatory inspectorate and Ethics Committees of variable quality meant that serious protocol violations and informed consent failures could persist undetected.
Judicial Intervention and the Reform Crisis (2011–2013)
The accumulation of documented failures triggered a response from India's judiciary that would reshape the regulatory landscape more dramatically than any planned reform.
In 2012, the Supreme Court of India took up public interest litigation challenging the adequacy of clinical trial oversight. The Court's intervention was not merely advisory — it resulted in direct orders to CDSCO and the Ministry of Health that fundamentally altered the regulatory environment:
- Suspension of new clinical trial approvals: CDSCO effectively halted new clinical trial approvals for a period as the Court examined regulatory adequacy. International sponsors who had planned to initiate trials in India found the pathway closed.
- Mandatory audiovisual documentation of informed consent: The Court ordered that informed consent processes be audiovisually recorded to create a verifiable record of participant understanding and voluntariness — a requirement unprecedented in major international regulatory jurisdictions.
- Limitations on investigator trial participation: Restrictions were placed on the number of active trials any single investigator could conduct simultaneously, addressing the overload problem that had been documented.
- Compensation determination framework: The Court directed development of a structured framework for determining compensation in trial-related injury and death cases, replacing the ad hoc case-by-case approach that had generated such controversy.
The period from 2012 to 2015 saw a dramatic contraction in India's clinical trial activity. The number of new IND applications approved by CDSCO dropped from 263 in 2012 to 17 in 2014 — a decline of more than 90%. International sponsors redirected development programs to other Asian markets. India's position as a global clinical research destination had, within the space of three years, been severely damaged.
Regulatory Reconstruction (2013–2018)
The period of severe restriction was followed by a more measured process of regulatory reconstruction — building the governance infrastructure that should have existed before the crisis, rather than simply reopening the trial pipeline to previous volumes.
Ethics Committee Registration and Standardization
The mandatory registration of Ethics Committees with CDSCO was one of the most consequential structural reforms of this period. Registration requirements established minimum standards for EC composition — requiring specified proportions of medical, scientific, legal, and lay members — operational procedures, member training, conflict of interest management, and record-keeping. ECs that could not meet these standards could not review clinical trials.
This reform did not create perfect Ethics Committees overnight. But it created a baseline of accountability and a mechanism for regulatory oversight of the review process itself — neither of which had previously existed.
The Compensation Framework
Detailed regulatory guidance established a structured methodology for determining compensation in cases of trial-related injury or death. The framework specified:
- Causality assessment methodology: A structured process for determining the degree to which a participant's injury or death was attributable to trial participation, the investigational product, or underlying disease
- Compensation quantum formula: A formula incorporating the participant's age, income, nature and severity of injury, and assessed degree of trial relatedness to determine compensation amounts
- Mandatory medical management: Sponsors were required to provide medical treatment for trial-related injuries, independent of compensation payments
- Timelines for determination: Defined timeframes for completing causality assessments and delivering compensation decisions
This framework — however imperfect in its initial form — transformed compensation from an ad hoc negotiation into a defined regulatory obligation with specified procedures and timelines.
Restructuring of CDSCO's Expert Review Process
The regulatory review architecture underwent significant structural reform:
New Drug Advisory Committees (NDACs) — the expert bodies that had previously reviewed clinical trial applications — were replaced by Subject Expert Committees (SECs), which were constituted with clearer mandates, defined membership criteria, and more transparent operating procedures.
A Technical Review Committee (TRC) was established as an additional layer of expert review for complex applications, providing a further check on regulatory decisions and reducing the concentration of decision-making authority.
These structural reforms increased the rigor and defensibility of regulatory decisions — at the cost of further slowing an already constrained approval pipeline during the transition period.
Rebuilding Approval Volume: A Gradual Recovery
The recovery in clinical trial approvals through 2015–2018 was gradual and deliberate. CDSCO prioritized quality of oversight over volume of approvals — a reversal of the implicit priorities that had characterized the rapid growth period. The number of approved trials increased year by year but did not return to pre-crisis volumes until the fundamental framework reform of 2019 provided a sustainable regulatory architecture.
The New Drugs and Clinical Trials Rules, 2019: A Comprehensive Legislative Overhaul
The New Drugs and Clinical Trials (NDCT) Rules, 2019 — enacted under the Drugs and Cosmetics Act, 1940, and replacing the legacy Schedule Y framework entirely — represent the most comprehensive reform of India's clinical trial regulatory framework since the Drugs and Cosmetics Act itself.
The NDCT Rules did not simply update existing provisions — they created a new regulatory architecture designed to address the failures of the pre-crisis period while positioning India for participation in modern, technology-enabled, globally integrated clinical research.
Defined Regulatory Timelines
One of the most significant practical improvements of the NDCT Rules is the establishment of legally defined timelines for regulatory decisions:
- 30 working days for clinical trial approval of new drugs already approved in ICH-member countries seeking to run simultaneous global trials in India
- 30 working days for other new drug clinical trial applications following SEC review
- Deemed approval provisions: If CDSCO fails to communicate a decision within the specified timeline, the application is deemed approved under defined circumstances — a provision with no precedent in Indian pharmaceutical regulation
These timelines transformed India's regulatory environment from one characterized by unpredictable multi-month or multi-year waits into one where sponsors could plan development programs with meaningful timeline certainty.
Simultaneous Global Trial Participation
The NDCT Rules explicitly permit simultaneous Phase I, II, and III trials — Indian sites can enroll patients at the same time as sites in the US, EU, Japan, and other ICH markets. This ended the historical practice of requiring India-specific trials to wait for global results — a requirement that had positioned India as a second-tier destination for international development programs and denied Indian patients early access to investigational therapies.
The scientific and ethical significance of this change extends beyond operational convenience. Simultaneous participation means that Indian patients contribute to the evidence base that supports global regulatory decisions — rather than being excluded from the research that generates treatments they will eventually use.
Strengthened Compensation and Medical Management
The compensation framework — developed in response to the judicial crisis — was codified and refined in the NDCT Rules, with clear provisions for:
- Mandatory medical management of trial-related injuries at the sponsor's expense
- Defined causality assessment procedures and timelines
- Compensation formula incorporating participant demographics, injury severity, and relatedness determination
- Post-trial access provisions for participants who benefit from investigational products that do not receive marketing authorization
Simplified Academic and Investigator-Initiated Trials
Recognizing that the regulatory burden of the post-crisis reform period had disproportionately affected non-commercial research conducted by Indian academic investigators, the NDCT Rules established a simplified regulatory pathway for academic clinical trials — reducing documentation requirements, fees, and approval timelines for non-commercial research conducted without industry sponsorship.
This provision acknowledged that India's domestic biomedical research capacity depends on sustainable pathways for investigator-initiated research, not only industry-sponsored multinational trials.
Orphan Drugs and Accelerated Approval Pathways
The NDCT Rules formalized accelerated approval mechanisms for drugs intended to treat serious or life-threatening conditions with unmet medical need — including orphan drugs for rare diseases. These provisions include:
- Priority review designation with shorter regulatory timelines
- Conditional approval based on surrogate or intermediate endpoints with post-approval confirmatory study requirements
- Waivers of local clinical trial requirements for drugs with established efficacy in similar populations internationally
These pathways are particularly significant for India's rare disease patient community — historically among the most under-served by both clinical research and access to approved therapies.
Digital Transformation and Regulatory Transparency
The NDCT Rules were accompanied by a broader digital modernization of CDSCO's operational infrastructure:
The SUGAM Portal
The SUGAM online regulatory submission portal replaced paper-based application processes for clinical trial applications, import licenses, marketing authorization applications, and other regulatory filings. SUGAM provides:
- Standardized electronic application forms
- Online document upload and version control
- Electronic fee payment
- Application status tracking accessible to sponsors
- Automated acknowledgment and communication workflows
The transition to SUGAM has improved submission consistency, reduced administrative processing time, and — critically — created a transparent, auditable regulatory workflow that reduces opportunities for the informal processes that had characterized the pre-reform era.
Mandatory CTRI Registration
Prospective registration of all clinical trials with the Clinical Trials Registry – India (CTRI) — operated by ICMR — became a legally enforceable requirement under the NDCT Rules. CTRI registration before first patient enrollment ensures:
- Public transparency about ongoing trial activity in India
- Accountability for trial conduct against registered protocols
- Contribution to the global clinical trial registry ecosystem (CTRI data feeds into the WHO's International Clinical Trials Registry Platform)
- A mechanism for identifying discrepancies between registered protocols and actual trial conduct during regulatory inspections
Online Regulatory Tracking
CDSCO's commitment to online tracking of regulatory decisions — with application status accessible to sponsors through SUGAM — represented a significant transparency improvement over the pre-reform era, when regulatory decision timelines were opaque and sponsors had limited visibility into where their applications stood in the review process.
India's Regulatory Alignment With International Standards
A defining characteristic of India's post-2019 regulatory framework is its systematic alignment with international regulatory norms — an alignment that enables India to participate as a peer in global development programs rather than as an adjunct market requiring special accommodation.
ICH E6(R2) GCP alignment: India's GCP requirements are aligned with the ICH E6(R2) Good Clinical Practice standard — the international benchmark against which regulatory agencies in the US, EU, Japan, and other ICH markets evaluate clinical trial conduct. This alignment means that data generated in Indian trials is credible to international regulatory agencies without requiring additional validation.
ICH guideline adoption: India has adopted or aligned with the principal ICH guidelines governing clinical development — including ICH M3(R2) on non-clinical safety studies, ICH E8(R1) on general considerations for clinical studies, and the ICH E2 series on pharmacovigilance — creating a consistent scientific framework across the development lifecycle.
Global pharmacovigilance integration: India's PvPI pharmacovigilance network is integrated with the WHO Uppsala Monitoring Centre's global signal detection infrastructure — meaning Indian safety data contributes to and benefits from global pharmacovigilance intelligence.
The Current Landscape: An Ecosystem Rebuilt
India's clinical research ecosystem in 2025 looks fundamentally different from the one that existed before the crisis — and the differences reflect deliberate regulatory choices rather than simply the passage of time.
Regulatory predictability: The defined timelines and deemed approval provisions of the NDCT Rules have transformed India from a jurisdiction characterized by unpredictable regulatory timelines into one where sponsors can build realistic development plans. This predictability is arguably the single most important factor in a sponsor's market entry decision.
Ethical governance infrastructure: The registered EC network — with defined composition, operating procedure, and accountability requirements — provides a level of ethical oversight quality consistency that was entirely absent before the crisis. India now has more than 250 CDSCO-registered Ethics Committees operating under standardized minimum standards.
Participant protection codification: Compensation frameworks, informed consent requirements (including the audiovisual documentation mandate), and post-trial access provisions together constitute a participant protection framework that — in its codified form — is more comprehensive than existed at any prior point in Indian regulatory history.
Growing CDSCO inspection capacity: CDSCO's GCP inspection program has expanded, with increasing numbers of clinical trial site inspections conducted annually. The existence of an active inspection program — with consequences for non-compliance — provides a deterrent function that was largely absent in the pre-crisis period.
Investigator network quality: The combination of EC registration requirements, investigator limitation provisions, and GCP training expectations has contributed to a gradual quality improvement in India's active investigator network — though training consistency and infrastructure quality variation across sites remains a legitimate concern for sponsors.
Unresolved Challenges and the Road Ahead
Honest assessment of India's regulatory evolution requires acknowledging what remains unresolved alongside what has been achieved:
SUGAM portal operational friction: While SUGAM has improved transparency and consistency, technical issues — including portal downtime, document format requirements, and electronic payment failures — continue to create operational delays for sponsors during the submission process.
EC quality variation: While registered ECs now operate under minimum standards, the gap between the best and least capable ECs remains significant. Review timelines, documentation quality, and scientific rigor continue to vary substantially — and sponsors cannot always predict which EC characteristics will affect their specific study.
Decentralized trial framework: India lacks a comprehensive regulatory guidance document for decentralized clinical trial elements — remote visits, home health nurses, ePRO, wearables — equivalent to the FDA's 2023 DCT guidance or EMA's corresponding framework. CDSCO has signaled awareness of this gap, but formal guidance is pending.
Real-world evidence framework: A structured regulatory pathway for RWE submissions to support label expansions, post-marketing requirements, or comparative effectiveness claims has not yet been formalized by CDSCO — though the data infrastructure required (ABDM digital health records, PvPI pharmacovigilance data) is developing.
Rare disease ecosystem: Despite the NDCT Rules' orphan drug provisions, India's rare disease patient community continues to face significant delays in accessing approved therapies. The gap between orphan drug approval provisions and actual patient access — driven by pricing, reimbursement, and supply chain factors beyond the regulatory framework — remains a significant unmet challenge.
Conclusion
The history of clinical research regulation in India between 2008 and the present is a story of crisis, consequence, and reconstruction — played out against the backdrop of a country navigating the tension between becoming a global scientific partner and protecting its most vulnerable citizens from exploitation.
The crisis of 2011–2015 was painful and costly — for sponsors who lost access to a valuable market, for investigators whose professional reputations were damaged by association, and most acutely for patients whose access to investigational therapies was delayed by years. But the reforms it catalyzed — the NDCT Rules, EC registration, the compensation framework, SUGAM, CTRI — produced a regulatory architecture that is genuinely more protective, more transparent, and more globally integrated than anything that existed before.
India's regulatory journey is not complete. The frontiers of decentralized trials, real-world evidence, artificial intelligence in clinical research, and advanced therapy medicinal products will test the adaptability of any regulatory framework. What the post-2019 environment demonstrates is that India's regulatory institutions have the capacity to learn from failure, respond to external pressure, and build frameworks commensurate with the complexity of modern clinical research.
That capacity — more than any specific regulatory provision — is the most important asset India's clinical research ecosystem possesses.
Genelife Clinical Research Pvt. Ltd. has operated throughout the evolution of India's clinical research regulatory landscape, building regulatory expertise and operational capabilities aligned with each phase of framework development. Visit www.genelifecr.com to learn about our regulatory services.
Related Insights
- CDSCO Approval Process for Clinical Trials in India: Complete Guide
- History of Clinical Research Regulation in India
- What is a CRO? Role of Clinical Research Organizations in India
- Clinical Trial Process in India: Step-by-Step Guide
No comments:
Post a Comment